Back

Show me the data: clinical efficacy, safety and indications of PCSK9 inhibition

26 August 2017 (11:45 - 12:07)
Organised by:
Congress Presentation Part of: PCSK9 inhibition - cholesterol reduction and beyond Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor J Wouter Jukema

Leiden University Medical Center, Leiden (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
A global view: the rationale for aggresive LDL lowering
Professor S. Nissen (Cleveland, US)
Slides Video
Presentation thumbnail
Cholesterol metabolism and the role of PCSK9
Professor S. Nicholls (Melbourne, AU)
Slides Video
Presentation thumbnail
Are there effects of PCSK9 inhibitors beyond cholesterol lowering?
Professor B. Cariou (Nantes, FR)
Slides Video

Access the full session

Session thumbnail
PCSK9 inhibition - cholesterol reduction and beyond

The Event

Event poster

ESC Congress 2017

26 August 2017 11:45 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources